eligibility_summary
Adults (≥18) with CD19/CD20+ LBCL refractory to or relapsed ≤12 mo after 1st‑line anti‑CD20+anthracycline, ECOG ≤2, adequate organ function, no active CNS lymphoma (treated, cleared allowed), HBV suppressed/HCV cured, ≥2‑wk washout/recovery, agree to hospitalization/contraception. Exclude prior CAR‑T/glofitamab, uncontrolled infection/HIV, CNS/cardiac disease, cardiac lymphoma, indwelling drains, urgent mass effect, major autoimmune, recent VTE, live vaccines, pregnancy, other investigational therapy, HLH, chronic EBV/CMV, transplant, PML, recent COVID.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm study in relapsed/refractory large B-cell lymphoma tests: 1) Axicabtagene ciloleucel (axi-cel): autologous CD19-directed CAR T-cell therapy (gene-modified T cells with CD28 costimulation) that recognizes CD19 on malignant B cells to drive T-cell activation and cytotoxic killing. 2) Glofitamab: T-cell–engaging bispecific antibody (CD20×CD3) that bridges CD3 on endogenous T cells to CD20 on B cells, forming an immune synapse to induce T-cell–mediated B-cell lysis, step-up dosing used. 3) Obinutuzumab: glycoengineered type II anti-CD20 monoclonal antibody used as pre-treatment to deplete peripheral B cells and mitigate CRS, mediating ADCC and direct cell death. Targets/pathways: CD19+ and CD20+ B cells, CD3 on T cells, T-cell activation/exhaustion, ADCC-driven B-cell depletion.